Assessment of the Efficacy Safety and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease

Brief description of study

The purpose of this study is to learn about the effects of a study medicine, Epetraborole, to assess the efficacy for treating refractory MAC, to see how safe Epetraborole is for patients with refractory MAC, to confirm the dosage, to understand how Epetraborole leaves the body, and to assess how patients feel while taking the study drug. The sponsor will also compare the effects of the study medicine, Epetraborole plus optimized background regimen, (OBR), with placebo plus OBR to find out which is better for treating MAC.

Clinical Study Identifier: s22-00181 Identifier: NCT05327803
Principal Investigator: Doreen J Addrizzo-Harris.
Other Investigator: Tejas Shah.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.